Trial Profile
Phase II clinical trial of docetaxel in combination with gemcitabine in platinum-resistant ovarian cancer and primary peritoneal carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 23 Jun 2009 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2008 Added lead investigator, from University of Southern California/Norris Comprehensive Cancer Center record.